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Abstract
Circulation is an important delivery method for both natural and synthetic molecules, but microenvironment interactions,
regulated by endothelial cells and critical to the molecule’s fate, are difficult to interpret using traditional approaches. In this
work, we analyzed and predicted growth factor capture under flow using computer modeling and a three-dimensional
experimental approach that includes pertinent circulation characteristics such as pulsatile flow, competing binding
interactions, and limited bioavailability. An understanding of the controlling features of this process was desired. The
experimental module consisted of a bioreactor with synthetic endothelial-lined hollow fibers under flow. The physical
design of the system was incorporated into the model parameters. The heparin-binding growth factor fibroblast growth
factor-2 (FGF-2) was used for both the experiments and simulations. Our computational model was composed of three
parts: (1) media flow equations, (2) mass transport equations and (3) cell surface reaction equations. The model is based on
the flow and reactions within a single hollow fiber and was scaled linearly by the total number of fibers for comparison with
experimental results. Our model predicted, and experiments confirmed, that removal of heparan sulfate (HS) from the
system would result in a dramatic loss of binding by heparin-binding proteins, but not by proteins that do not bind heparin.
The model further predicted a significant loss of bound protein at flow rates only slightly higher than average capillary flow
rates, corroborated experimentally, suggesting that the probability of capture in a single pass at high flow rates is extremely
low. Several other key parameters were investigated with the coupling between receptors and proteoglycans shown to
have a critical impact on successful capture. The combined system offers opportunities to examine circulation capture in a
straightforward quantitative manner that should prove advantageous for biologicals or drug delivery investigations.
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Introduction
The bioavailability of molecules as they circulate through the
bloodstream is a crucial factor in their signaling capability. Half-
life in circulation can determine the effectiveness of a drug simply
by regulating the opportunities a molecule has to interact with the
vessel wall. Although in vivo measurements are routinely made by
researchers to monitor serum levels of molecules and to determine
half-lives, interactions in the microenvironment are not easily
measured or observed. While some molecules may have a long
circulation life, many may have only a single opportunity to
interact with the blood vessel walls before being filtered through
the liver or kidneys. In addition, even molecules with a long
circulation life may still face impediments to direct interaction with
the endothelium. This, for example, is the case with vascular
endothelial growth factor (VEGF) when bound to bevacizumab, a
monoclonal antibody to VEGF [1,2]. Bevacizumab has been
shown to increase the circulating concentration of VEGF in cancer
patients when compared to patients not undergoing therapy
because of the increased half-life of the growth factor-antibody
complex; however the complex is unable to bind to VEGF
receptors [3] making delivery of the VEGF questionable. In order
to better understand the vessel microenvironment and to
accurately monitor drug interactions in the context of that
microenvironment, better tools are needed to provide meaningful
measurements that can predict the fate of molecules in circulation.
Many important measurements have and continue to be made
using in vitro mammalian tissue culture methods but there are
obvious limitations to the traditional two-dimensional culture
approach. In circulation, the influence of flow on whether a
molecule remains in the fluid phase or binds to the vessel wall can
be a dominant factor. This influence cannot be ascertained in
static tissue culture studies. For example, the velocity of blood in
the aorta is ,400 mm/sec while at the capillary level it is less than
1 mm/sec [4]. This reduction in velocity allows the exchange
processes at the capillary level to take place more efficiently [4]
and it likely also affects the activity of molecules in circulation that
rely on cell surface binding in order to fulfill their roles. While
direct measurement of this binding process is difficult, our model
makes use of a commercial bioreactor with endothelial-lined
hollow tubes operating under pulsatile flow to mimic the vascular
environment architecture and to directly measure the loss of
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single pass method to allow better assessment of the effect of flow
in either retaining molecules in the circulation or permitting their
interaction with vessels. Our approach also makes use of a bolus
administration, since this is a typical way in which drugs would be
delivered in a clinical setting.
The binding of fibroblast growth factor-2 (FGF-2) to its cell
surface receptor (FGFR) and the role of heparan sulfate
proteoglycans (HSPG) in regulating the process have been of
research interest for many years because of their role in
angiogenesis, the growth of new blood vessels from existing
vessels. Knowledge of how these processes work could aid in the
development of new therapeutics to control tumor growth and
assist clinically in the treatment of chronic wounds. In order to
understand the mechanism of FGF-2-mediated cell proliferation, a
multitude of experimental studies have been undertaken [5] and,
in the past two decades, several computational models of FGF-2
binding to its receptor FGFR and HSPG have been proposed [6–
11]. Insight can be gained through experiment-coupled modeling
that could not otherwise be readily obtained. Nugent and Edelman
[11] were among the earliest researchers to develop a simple
model that includes three species, FGF-2, FGFR and HSPG. They
measured kinetic binding rate constants experimentally and used
their model to analyze the data thereby providing a foundation for
investigating the complexity of FGF-2 binding. A similar approach
was used by Ibrahimi et al [9] to investigate stepwise assembly of a
ternary FGF-2-FGFR-HSPG complex in conjunction with their
surface plasmon resonance measurements. We introduced more
complexity into the FGF-2 binding model with the inclusion of
heparin binding [12], receptor dimerization [8], and formation of
alternative HSPG-FGFR species [13]. Recent models have moved
towards including intracellular signaling [14]. With the exception
of work by Filion and Popel [7,15], which included diffusive
transport, previous simulation work has been based on a static
tissue culture environment that may be quite different from the
dynamic in vivo environment of blood vessels.
We introduced a computational model based on a flow
environment in which the competitive binding of FGF-2, FGFR,
and HSPG in a pulsatile flow environment was addressed to mimic
blood vessel-like hollow fibers [16,17]. In this paper we use an updated
version of that model to explore how specific parameters such as flow
rate impact FGF-2 capture and receptor binding, and compare our
results with experimental studies. Insights with regard to the
importance of surface coupling and ligand depletion zones within
the fluid phase werefound.Thedescribedsimulationpackage provides
a new and valuable way to investigate growth factor capture and can
be easily extended to other biologically relevant molecules and drugs.
Materials and Methods
Preparation of Bovine Aortic Endothelial Cells (BAECs)
BAECs (passage 10), cryopreserved in liquid nitrogen, were
cultured in Dulbecco’s modified Eagle’s medium (DMEM-low
glucose, phenol red-free, Invitrogen Corporation, Grand Island,
NY), supplemented with penicillin (100U/mL, Invitrogen Corpo-
ration, Grand Island, NY), streptomycin (100mg/mL, Invitrogen
Corporation, Grand Island, NY), glutamine (2mM, Invitrogen
Corporation, Grand Island, NY), and 5% newborn calf serum
(Invitrogen Corporation, Grand Island, NY). When a sufficient
number of cells were grown (passage 11,13), they were
transferred to the hollow fiber cartridge.
Preparation and maintenance of endothelial cartridges
The FiberCell polysulfone plus endothelial cartridges (C2025,
FiberCell Systems Inc., Frederick, MD), also called hollow fiber
bioreactors, contain 20 capillaries which are 12 cm long, 700 mm
I.D., 300 mm wall, 0.1mm pore size, 53 cm
2 lumen surface area
(Figure 1A). They were activated with 70% ethanol (Fisher
Scientific, Houston, TX), followed by multiple washes with sterile
distilled water. The cartridges were then coated using 5 mg/mL
fibronectin (Sigma Aldrich, St. Louis, MO) in phosphate buffered
saline (PBS, Invitrogen Corporation, Grand Island, NY). BAECs
(passage 11,13) were inoculated into the cartridges (0.7–1610
7
cells/cartridge) 24 hours after the coating and placed in an
incubator for 4 hours (rotated 180u after 2 hours) without flow in
order to promote cell attachment. The BAEC culture cartridges
were then linked to the FiberCell pump system (FiberCell Systems
Inc., Frederick, MD) and media circulated through the system at
,2.6 mL/minute (5.2 mm/sec). The flow system was maintained
in the incubator (37uC, 5% CO2) at all times except during the
experiment periods. Cell growth and viability was monitored by
measurement of the cell glucose consumption from the medium
once a day with OneTouch UltraSmart blood glucose monitoring
system (Lifescan, Inc., Milpitas, CA).
Growth factor flow studies
The flow system and cell-lined cartridges were removed from the
incubator, gently washed once with warmed (37uC) PBS (60 mL),
and then maintained in circulating 125 mL serum-free medium
(DMEM-low glucose, phenol red-free, supplemented with 0.05%
gelatin in PBS) in a sterile room-temperature tissue culture hood
(Thermo Scientific, Waltham, MA). After establishing flow at the
desired rate (low rate: 0.60,0.68 mL/min (1.2–1.36 mm/sec); high
rate: 1.6–1.8 mL/min (3.2–3.6 mm/sec) or 2.9–3.0 mL/min (5.8–
6.0 mm/sec)) with a CellMax Quad pump (Spectrum Laboratories,
Inc.) for about 2 minutes, flow was stopped to allow the growth
factorofinterest(FGF-2(SigmaAldrich,St.Louis,MO),EGF (R&D
Systems Inc., Minneapolis, MN) and VEGF (R&D Systems Inc.,
Minneapolis, MN)) (0.11 mL) to be injected into the inlet. After the
injection, the flow was resumed and the flow media collected (two
drops/fraction) for the desired time period. The flow pattern was
assumed to be sigmoidal based on previous studies [18,19]. The
cartridges were then gently washed with warmed PBS supplemented
with0.3MNaCl(10 mL)followedbyonewashwith10 mLPBSand
a wash of the whole flow system with PBS (60 mL). The system was
returned tothe sameculturemediaand flowratesasdescribedunder
Preparation of BAECs, allowing at least 24 hours before the next
Author Summary
In this work we have investigated the role of a family of
cell surface molecules, proteoglycans, in blood vessel
capture of proteins important to normal and diseased
states under flow conditions. We developed a computer
model to analyze and predict these events and, using an
experimental system incorporating endothelial-lined hol-
low fibers as model blood vessels, tested our predictions.
We found that both proteoglycans and flow exert
significant influence over growth factor binding to the
vessel wall. Removal of proteoglycans significantly reduced
binding of these proteins; and flow rates slightly higher
than that seen in capillaries had a similar effect, albeit in a
different way. This knowledge will increase our under-
standing of interactions inside blood vessels and help to
design more efficient pharmaceuticals. Also, our computer
model has the potential to test the ability of existing and
future drugs and biologics to successfully target blood
vessels.
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experiments were stored at 4uC and analyzed with ELISA kits (R&D
Systems Inc., Minneapolis, MN) within the next 24,48 hours.
Viscosity measurements
Dynamic viscosity of the test cell culture medium was measured
using a DV-II++ Pro Programmable cone-plate viscometer (cone
#CPE-40; Brookfield Engineering Laboratories; Boston, MA)
according to the manufacturer’s instructions. Viscosity measure-
ments were made for a range (375 to 750 sec
21) of shear rates (to
confirm Newtonian fluid behavior) at room (i.e., 25uC) and
physiologic (i.e., 37uC) temperatures.
Enzymatic treatment
Heparan sulfate expression was measured in static tissue
culture dishes and in the flow cartridge by heparinase treatment
Figure 1. The bioreactor system. (A) A diagram of the experimental set-up, and (B) brightfield and DAPI stained images of endothelial cells from
the unit showing the continuous vessel-type architecture.
doi:10.1371/journal.pcbi.1000971.g001
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quantitation using a dimethylene blue colorimetric assay [20,21].
Cells in static culture contained 4.3+/20.31610
26 mg of heparan
sulfate/cell and cells in cartridge hollow fibers contained 1.1+/
20.09610
26 mg of heparan sulfate/cell, reflecting an ,75%
reduction in cell surface heparan sulfate under flow (0.63 mL/min
(1.26 mm/sec)).
Heparinase III (0.01 unit/0.11mL, Seikagaku Corp., Japan;
0.2unit/0.11mL, Sigma Aldrich, St. Louis, MO), chondroitinase
ABC (0.2 unit/0.11mL, Seikagaku Corp., Japan) and keratanase
(0.33unit/0.11mL, Sigma Aldrich, St. Louis, MO) were utilized
to observe their effect on growth factor flow and binding. In
some experiments, the enzymes (heparinase III, chondroitinase
ABC and keratanase) were mixed together as an enzymatic
cocktail solution at the above concentrations. Cartridges were
treated for 20 minutes at 37uC, washed with warmed PBS
(10 mL), and growth factor studies performed as described
above.
Determination of non-specific binding
Non-specific binding of FGF-2 in the system was determined to
be primarily due to the inlet reservoir. The reservoir chamber was
removed from the cartridge, growth factors were injected into the
inlet of the cartridges with a syringe, and flow was initiated.
Fractions were collected as they exited the reservoir. Growth
factors were measured before injection and compared to the sum
of the collected fractions. The difference between the input
amount and the amount collected constituted the nonspecific
binding in our experiments. For FGF-2 (1.0+/20.1 ng), the
amount retained in the reservoir was 29+/22.8% of the FGF-2
added (SD, n=3). Additional nonspecific binding within the
hollow fibers was assumed to be minimal.
Determination of growth factor concentration in outflow
The concentrations of FGF-2, EGF, and VEGF in the collected
fractions were measured by ELISA. The flow rate of each
experimental run was determined from the total volume collected
divided by the total flow time.
Immunofluorescent staining of BAECs from the
bioreactor flow system
To visualize the BAECs cultured in the flow system, cartridges
were washed with PBS supplemented with 0.5M NaCl to extrude
the endothelial cell lining from the hollow fibers and then the cell
linings were fixed with 4% paraformaldehyde (Electron Micros-
copy Sciences, Hatfield, PA) in PBS for 10 minutes. Three washes
with PBS (one minute per wash) followed and the cell linings
permeabilized with PBS supplemented with 0.03% Triton and 1%
BSA for 3 minutes on a shaker platform at room temperature. The
cells were then treated with 10 mg/mL 49, 6-diamidino-2-
phenylindole (DAPI) (Sigma Aldrich, St. Louis, MO) in PBS
supplemented with 0.03% Triton and 1% BSA for 20 minutes,
followed by three PBS washes for 2 minutes each at room
temperature. The cells were then visualized and photographed
using a Nikon Eclipse TE 2000E fluorescent microscope (Nikon,
Melville, NY) at an excitation wavelength of 350 nm (Figure 1B).
Model development
The computational model is based on the physical dimensions
of the bioreactor although the system is scalable to other desired
dimensions. The domain of the simulation is the hollow-fiber
portion of the cartridge (Figure 1). The computational model has
three coupled parts: (1) the medium flow equations; (2) the
convective mass transport equations of growth factor in the flow;
(3) the binding kinetics equations on the wall of the fibers [8,16].
In order to solve the coupled equations numerically and
efficiently, the following assumptions are made: (1) the walls of the
hollow fibers are rigid and nonporous; (2) the flow is axisymmetric
and laminar; (3) the fluid is incompressible, Newtonian and
isothermal; (4) all of the hollow-fiber capillaries within the
cartridge have the same dimensions, flow rate, cell densities and
entrance conditions; and (5) the cells are packed tightly and
distributed evenly on the wall of the hollow-fiber capillaries.
Entrance effects of the flow are ignored [22,23] and, consequently,
the flow within the fibers is treated as fully developed flow in which
the radial velocity is neglected. A uniform mesh is used. The
kinetic pathways are shown in Figure 2 and the equations and
parameter values are included in Tables 1 and 2, respectively.
Figure 2. Schematic of reaction pathways on the cell surface. FGF-2 is the only species in the fluid phase with all reactions included in the
model occurring on the cell surface and incorporated in the model as boundary conditions.
doi:10.1371/journal.pcbi.1000971.g002
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reservoir where it is assumed to quickly reach a uniform
concentration. The concentration of FGF-2 in the reservoir is
assumed to decrease gradually as fluid is pumped into the reservoir
prior to distribution into the capillaries with each pulse cycle as:
1
n
ent~1
n{1
ent |
v{Dv
v
where v is the volume of the reservoir, Dv is the volume of fluid
flowing into the fibers at each pulse, 1
n
ent is the current and 1
n{1
ent
is the previous concentration of FGF-2 in the reservoir. 1
0
ent~
F0
v
,
where F0 is the amount of FGF-2 injected. The pump pulse cycle
was measured experimentally and determined to be ,36 strokes/
min at a flow rate of 1.4 mm/sec.
Pulsatile flow is treated in the following manner. A pulse of fluid
volume enters the pre-pump inlet reservoir (0.4 mL volume), from
which a continuous flow of fluid having an axial velocity greater
than or equal to zero enters the cell-lined fibers in the cartridge.
The axial velocity is oscillatory but with only positive terms.
Entrance effects are considered negligible [23]. The velocity of the
fluid in the axial direction is determined with the following
formula [17]:
u(r,t)&
2qs
NfpR2 (1zcosvt)(1{
r2
R2 )
where qs is the average volumetric flow rate, Nf is the number of
fibers inside the cartridge, R is the radius of a fiber, v=2p/T is the
angular frequency of the pulsatile flow, and T is the pump pulse
cycle.
Good agreement between the simulation and experimental
results was determined based on two criteria: an amount criterion
and a curve-matching criterion. The amount criterion is defined
as:
DMexp{MsimD
M
v1%
where Mexp is the outflow amount of protein determined
experimentally, Msim is the outflow amount determined within
the simulations and M is the amount of FGF-2 entering the
capillary. The curve-matching criterion is calculated in the
following way. The FGF-2 exit profile curve is not a continuous
curve but is a series of discrete values at different time intervals.
This makes use of traditional curve matching algorithms difficult.
Our method aligns the initial exit times for the simulations and
experiments and then calculates the distance between points on
the two outflow curves using the following formula:
D~
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
PN
i~1 ai{bi ðÞ
N
2
s
where N is the total number of time intervals. ai and bi is the
amount of FGF-2 exited at the ith time interval in experiment and
simulation, respectively. The curve-matching criterion is defined
as:
D
M
v 2%
A special program written in C/C++ that operates under
Windows XP or Vista operating system has been built for solving
this model and has been described previously [16,17]. The
interface allows users to easily set parameters related to the
simulation such as FGF-2 injected concentration, flow rate, mesh
size, time step, and total simulation time via either configuration
text files or from the computer interface. The mass transport of
FGF-2 within the fiber is visualized in real time during the
simulation process. A Linux version of the software is also
available however it lacks a user interface tool and there is no real
time visualization. The binary code can be downloaded from
www.cs.uky.edu/,czhanb/research.html.
Table 1. Equations describing the binding reactions.
V
dF
dt
~{kaFRFRzkdFRCzkdFHRT{kaFHFHzkdFHG
(1)
dR
dt
~{kaFRFRzkdFRCzkaFHRT{kcRG{kintRzkintR0
(2)
dH
dt
~{kaFHFHzkdFHGzkdFHRT{kcCH{kintHzkintH0
(3)
dC
dt
~kaFRFR{kdFRC{kcCH{kcC2z2kucC2{kintC
(4)
dC2
dt
~
kc
2
C2{kucC2{kintDC2
(5)
dG
dt
~kaFHFH{kdFHG{kcRG{kcG2z2kucG2{kintG
(6)
dG2
dt
~
kc
2
G2{kucG2{kintDG2
(7)
dT
dt
~kcRGzkcCH{kdFHRT{kcT2z2kucT2{kintT
(8)
dT2
dt
~
kc
2
T2{kucT2zkintDT2
(9)
Cells line the walls of the hollow fiber tube in our model and growth factor can
bind to both receptors (R) or HSPG (H) to form complexes (C or G, respectively).
These complexes can dimerize (C2 or G2,) or form heterodimers (T) that can then
form higher order complexes (T2). The equations that describe the binding
reactions are listed as well as the parameters (Table 2) and initial conditions
used for the simulations.
The initial condition for the FGF-2 concentration (F) was based on the amount
of FGF-2 injected and the volume of inlet reservoir as described in Materials and
Methods. The concentration is assumed to be uniform across the entrance. The
receptor and HSPG densities were the initial conditions for R and H respectively.
All other variables had an initial value of zero.
doi:10.1371/journal.pcbi.1000971.t001
Table 2. Parameter values used in simulations.
Parameter Value Parameter Value
kaFR 3.2610
8 M
21min
21* kintD 0.078 min
21*
kdFR 0.28 min
21* R0 1610
4 # cell
21&
kaFH 1.2610
8 M
21min
21* H0 2.5610
5 # cell
21%
kdFH 0.56 min
21& rcell 800,000 # fiber
21%
kc 0.0024 (#/cell)
21 min
21‘ v 4.7610
212 L cell
21
kuc 0.6 min
21‘ rfluid 1000 kg m
23
kdFHR 0.018 min
21& m 0.00094 Pa?s
%
kint 0.005 min
21* D 1.67610
210 m
2 s
21&
*[47] but scaled to 25uC except for kint and kintD.
&[7] but scaled to 25uC except for R0.
‘[48].
%measured.
doi:10.1371/journal.pcbi.1000971.t002
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cells/cartridge, a value which was obtained from the experimental
system. The tolerance for solving the mass transport PDEs was set
at 10
212. The relative tolerance for solving the kinetic ODEs was
set at 10
28 and the absolute tolerance was 10
212.
Statistics
All experiments were performed a minimum of three times in
independent cartridges. The mean of all replicates 6 standard
deviation of those replicates is presented except where discrete
measurements were used to more closely represent small changes
in initial concentration. Significance (p,0.05) was determined
using a Student t-test with a two-tail distribution and unequal
variance (Excel, Microsoft).
Results
Endothelial cells form a uniform and confluent
monolayer in cartridge capillaries
Endothelial cells line blood vessels and are the initial entry point
for access of blood-borne proteins to the underlying tissue. Our
investigations focused on flow and the impact it has on endothelial
cell capture of growth factors, which are important regulators of
cell and tissue activity. To better approximate the microenviron-
ment of a blood vessel, we seeded bovine aortic endothelial cells
into the FiberCell cartridge system and cultured the cells under
flow (Figure 1A). Cell viability was confirmed for up to 8 weeks
and cell density was ,0.3610
6/cm
2. The geometry is clearly more
similar to in vivo than typical cell culture dishes but it was
important to obtain a uniform and confluent monolayer of cells
within the cartridge system to correctly perform and analyze
experiments. To confirm this, cartridges were treated with a high
salt wash to extrude the cell-based vessel and the cells were fixed
and imaged (Figure 1B). An incision was made at one end to
expose the lumen and demonstrate the continuity of the cell layer.
There is significant capture of FGF-2 under low flow
The average fluid velocity in human capillaries is ,1 mm/sec
[4]. We hypothesized that capture of regulatory growth factors
from solution would be significant at these flow rates thereby
facilitating growth factor activity. Using the lowest velocity setting
with the standard pulsatile pump included with the Cellmax
system (,1.3 mm/sec, ,0.65 mL/min), FGF-2 (5.060.4 ng) was
injected into the cartridge inlet reservoir and flow was com-
menced. As shown in Figure 3, there is a delay in FGF-2
appearance in the outflow corresponding to the time for FGF-2 to
travel through the cartridge and exit the system. The majority of
FGF-2 added exited the cartridge as a large peak approximately
1 mL (or 1.5 min at this flow rate) after flow was initiated. Non-
specific binding within the injection cartridge reservoir was
measured directly (31+/22.5%). Specific binding within the cell-
lined hollow fibers accounted for 9+/22.5% of total FGF-2 added
to the cartridge at this concentration and ,13% of the FGF-2
entering the cell-lined fibers, after taking into account non-specific
binding (Figure 3). The results shown in Figure 3A are from three
independent experiments conducted using three different cartridg-
es illustrating the reproducibility of the system. Repeat runs
conducted using the same cartridge as well as runs using
radiolabeled FGF-2 instead of unlabeled FGF-2 both produced
similar results (data not shown). The peak appearance time or
volume in the outflow from the cartridge was insensitive to FGF-2
injection concentration in the range studied (data not shown).
However, the size of the FGF-2 peak correlated with the injection
Figure 3. Significant retention of FGF-2 occurs under flow. (A)
FGF-2 (5.0+/20.4 ng) was injected into the inlet reservoir, pumped
through the cartridge at 0.65+/20.01 mL/min (1.3 mm/sec), and
measured in the output stream samples from three independent runs
on three separate cartridges. The average retention of FGF-2 within the
cell-lined cartridge was 40+/20.5% FGF-2 (mean +/2 standard deviation
of the three runs shown) with a specific binding of 9+/22.5% (B) FGF-2
((N)0 . 9 2n g,( #) 6.9 ng, (X) 12 ng, and (&) 18 ng FGF-2) was injected
into the initial reservoir, run through the system at 0.64 mL/min, and the
FGF-2in theoutput streammeasured usingELISA. (C) FGF-2(ng) retained
within the cell-lined cartridge versus the FGF-2 (ng) injected into the
system is shown. The flow rate for this study varied between 0.60 and
0.67 mL/min (1.2 and 1.34 mm/sec respectively). Results are from
individual runs with 9 independent cartridges.
doi:10.1371/journal.pcbi.1000971.g003
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concentration of FGF-2 added (Figure 3B).
The accuracy of our measurements took into consideration
specific losses that occurred with injection (i.e. tube, syringe,
needle, and reservoir). Rather than averaging datasets with
variable FGF-2 reservoir values, we therefore present them as
discrete results. A plot of total FGF-2 retained at these discrete
concentration points shows a dose responsive binding curve,
reflecting the linear portion of the binding curve expected at sub-
saturation ligand concentrations (Figure 3C).
Heparinase treatment significantly increases the FGF-2
outflow
Heparan sulfate proteoglycans (HSPG) are ubiquitous mole-
cules found on virtually all cells including endothelial cells and
have been shown to regulate heparin-binding growth factor
binding and activity in tissue culture [6,24–28]. FGF-2 is a
heparin-binding molecule associated with a number of physiologic
and pathologic processes [29] and, therefore, the role of HSPG in
regulating FGF-2 retention under flow was examined. Although
the binding affinity of FGF-2 for HSPG has been shown to be
lower than the affinity for the FGF receptor, these HSPG sites can
provide up to a thousand fold more binding sites for FGF-2 [6,24]
significantly impacting the cell binding ‘‘potential’’ for heparin-
binding growth factors. Cartridges were treated with heparinase,
an enzyme specific for heparin and heparan sulfate, and FGF-2
outflow quantified. After heparinase treatment, FGF (,1 ng) was
injected and pumped through the cartridge. Almost 74% of the
total FGF-2 added to the system was recovered in the outflow,
compared to ,46% of the total FGF-2 recovered from the non-
heparinase treated cartridge prior to subtraction of non-specific
binding. The amount of FGF-2 retained in the cartridge after
heparinase treatment corresponded to the measured level of non-
specific binding and thus indicated no specific binding to cell-lined
fibers in the absence of HSPGs (Table 3). In contrast, 25% of the
FGF-2 pumped through untreated cartridges was retained after
subtraction of non-specific binding. Although FGF-2 can bind to
its receptor in the absence of HSPG stabilization, that binding,
based on the apparent KD of the receptor for FGF-2 in the
absence of heparan sulfate, the lower level of FGFR generally
found, and the ligand-receptor exposure time under flow, would be
expected to be at least ten-fold lower than in the presence of
HSPG [24] and our data certainly support this.
To ensure that the effect with heparinase under flow was due to
the specific removal of heparan sulfate and not a general effect due
to enzymatic treatment of the cartridge or the enzyme incubation
process, the cartridges were treated with keratanase, an enzyme
having no specific known target on these cells. Keratanase, as
opposed to heparinase, had no significant effect on FGF-2
retention (Table 3). Interestingly, there was a small but re-
producible reduction (,9%) after chondroitinase treatment on
FGF-2 retention compared to control. Chondroitin sulfate
proteoglycans are typically found on vascular surfaces but FGF-2
has not been shown to bind directly to chondroitin sulfate [30,31].
It is not known at this time what the cause for the reduced binding
is, although it has been reported that both chondroitin sulfate and
dermatan sulfate under certain circumstances are able to influence
FGF binding [32–34].
VEGF but not EGF is impacted by heparinase treatment
VEGF, a heparin binding protein, and EGF, which does not
bind heparin, were next tested in this system. Both the initial
appearance time and outflow volume for the protein as well as the
general shape of the outflow peak for both VEGF and EGF were
similar to FGF-2 (Figure 4). To ensure that the measured effects
seen with heparinase-treatment on FGF-2 retention were due to
specific responses of the growth factor to the removal of heparan
sulfate and not a general response by all proteins, flow studies were
done with VEGF and EGF following enzymatic treatment. EGF
retention and outflow were unaffected by treatment with a cocktail
of heparinase, chondroitinase, and keratanase (Table 4). Treat-
ment with heparinase without chondroitinase or keratanase also
had no effect on EGF retention or outflow (data not shown). In
contrast, VEGF showed a significant decrease in specific retention
between control and heparinase treated cartridges (16+/25.8%
versus 22.5+/26.1% VEGF retained) indicating the critical role
HSPG can have in heparin-binding growth factor capture under
flow. The lack of a change in EGF binding or outflow profile
under heparinase treatment is supportive that there are no gross
changes in the cell glycocalyx that might impact the shear stress in
the system.
Simulations capture critical properties of process
Capture of FGF-2 by endothelial cells within the vasculature is a
critical step in growth factor activity and our bioreactor is an
excellent tool for investigating the capture process. However, it has
limitations with regard to quantification of cellular binding
behavior. The cartridges are expensive for short-term experiments
and culture time and preparation can be relatively lengthy.
Visualization of individual cell behavior within the culture is not
feasible. In addition, the ability to predict the capture of molecules
by cells under flow has value across a wide range of areas and the
development of a flow-based tool for the design and testing of
mechanisms related to retention is desireable. Our computer model
was designed based on media flow equations and mass transport
equations [35] with cell surface reaction equations to reflect the cell-
growth factor interactions (see Materials and Methods-Model
development). To validate the model, simulations were performed
using the variables (ie FGF input concentration and flow rate)
specific for an experimental series and a comparison was made.
ExperimentaltrialswereruninwhichFGF-2(0.92 ng)wasaddedto
the reservoir, pumped through the cartridge, and outflow collected
and analyzed for FGF-2. FGF-2 in the outflow showed a
characteristic peak outflow approximately 100s after flow was
initiated at 0.63 mL/min (1.26 mm/sec) and 1766.3% of the input
FGF-2 was retained within the cartridge after non-specific binding
was subtracted (Figure 5). Simulations performed using the same
input FGF-2 value and flow rate were run and comparison was
made between the simulations and experimental outflow from
control (Figure 5A) or heparinase-treated (Figure 5B) cartridges. We
defined good agreementbasedontwocriteria;the amountofFGF-2
recovered and the curve similarity. Criteria one requires the relative
Table 3. Heparinase and chondroitinase but not keratanase
impact FGF-2 output.
Treatment
FGF-2
input(ng)
% FGF-2
retained
flow rate
(mL/min)
control 0.95+/20.05 25+/21.7 0.62+/20.02
heparinase 0.92+/20.00 0.0+/22.9* 0.66+/20.02
chondroitinase 1.73+/20.68 16+/24.1* 0.65+/20.03
keratanase 0.95+/20.15 20+/27.5 0.62+/20.08
Mean +/2 standard deviation of at least three experimental runs.
*indicates significantly (p,0.05) different from control.
doi:10.1371/journal.pcbi.1000971.t003
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studies to be less than 1% while the second criteria compares the
actual amounts of FGF-2 exiting from the experimental and the
simulation system (see Materials and Methods). We did note that
FGF-2 retention with the simulations was very dependent on the
level of HSPGs with higher densities resulting in too much retention
via HSPG-FGF-2 binding and subsequent FGFR coupling while
lower HSPG densities resulted in too little retention (data not
shown). Comparison of simulation results with our heparinase-
treateddata showedfine agreementwithregardtoourcriteria when
non-specific loss in the reservoir was subtracted.
Pulsatile and steady flow results are similar at low flow
Capillary flow is generally steady, and gradually becomes
pulsatile at higher flow rates. We conducted simulations and in vitro
Figure 4. EGF and VEGF are retained under flow. (A) EGF (1.49 ng) was injected into the input reservoir, pumped through the system at
0.61 mL/min (1.22 mm/sec), and EGF quantified in the output flow by ELISA. Data shown are from the same cartridge either untreated (#)o r
enzyme-treated (N). FGF-2 (1.01ng - x) is shown for comparison. (B) VEGF was injected into the input reservoir of untreated (0.95ng - #)o r
heparinase-treated (0.98ng -N) cartridges, run through the system at 0.66 mL/min (1.32 mm/sec), and VEGF quantified in the output flow by ELISA.
Data are representative of at least three runs quantified in Table 4.
doi:10.1371/journal.pcbi.1000971.g004
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rate (0.6 mL/min, 1.2 mm/sec) to determine whether our model
would predict differences between FGF-2 interactions using steady
and pulsatile flow. Simulations predicted no difference in FGF-2
binding at low flow using pulsatile flow conditions versus steady
flow in either the FGF binding down the cell-lined hollow fiber
(Figure 6A) or in the profile of the outflow (Figure 6B). In vitro
experiments were performed using a syringe pump for steady flow
and the bioreactor’s pulsatile flow pump (Figure 6C). FGF-2
outflow measurements indicated no overall change at 0.6 mL/min
(1.2 mm/sec) suggesting that, at low rates typical of capillary flow,
no significant change in FGF-2 interactions takes place.
Simulations predict peak FGF-2 binding at entrance to
the cell-lined hollow fibers
Our experimental system does not allow easy separation
between internalized FGF-2 and that bound to the cell surface
or visualization of FGF-2 distribution within the cell-lined hollow
fiber. Using our computer model we examined how FGF-2 would
be distributed with respect to time after flow was initiated
(Figure 7). At a relatively low flow rate (0.63 mL/min, 1.26 mm/
sec), the FGF-2 in the reservoir had essentially all entered the
hollow fibers by 150s and the peak outflow of FGF-2 was evident
,200s after flow was initiated corresponding to the time when the
bulk FGF-2 had exited the hollow fibers. Later times showed cell-
bound FGF-2 either internalized or dissociated from the cell
surface with little chance to reassociate. The vast majority of
binding is predicted to occur near the entrance to the cell-lined
hollow fibers as opposed to the middle or end of the fibers
(Figure 7B). The impact of time was more pronounced in the front
section also as fluid entering the hollow fiber after ,150s was
devoid of FGF-2 (,0.1% of initial FGF-2). Increasing the diffusion
rate for FGF-2 in solution by increasing the diffusion coefficient by
an order of magnitude is predicted to have a negligible impact on
FGF-2 capture in the front of the capillary but increased
significantly the FGF-2 bound down the length of the cell-lined
hollow fiber. This was due to changes in the depletion zone near
the cell-lined walls (Figure 8). After 44s, an FGF-2 depletion zone
near the surface was evident which was reduced when the diffusive
transport of FGF-2 was increased. The replenishment of FGF-2
near the wall promoted greater FGF-2 binding as complex
formation is a second-order process and illustrates the importance
of surface depletion in growth factor capture.
Flow rate impacts FGF-2 binding
Our simulations indicate that depletion near the cell surface
impacts binding and suggests that residence time in the vicinity of
the cell surface is important. We therefore looked at how flow
impacted cell binding of FGF-2. Simulations predict that cell
binding is significantly diminished with increased flow rate
(Figure 9A) although the basic result of high binding at the
entrance and reduced binding down the cell-lined hollow fiber was
consistent across flow rates examined (data not shown). This
difference was evident regardless of the concentration of FGF-2
introduced to the system with the difference being more
pronounced at higher flow rates (Figure 9B). Reduction in binding
due to the loss of HSPG is less evident at higher flow rates where
the specific binding was already greatly reduced. This inverse
relationship between flow and cell binding is potentially important
especially at these relatively low flow rates. The highest rate used
in our simulations (,3 mL/min,,6 mm/sec) is considerably
lower than average arterial flow rates (100–400 mm/sec) in larger
vessels of the circulatory system [4] suggesting that, with a short
half-life, retention may be relevent only in small vessels with lower
velocities. Note that simulations were run to a constant time rather
than volume to reduce small fluctutations in retained FGF-2 due
to dissociation effects.
Experimentally, we found results that were consistent but not
quantitatively exact with this model prediction (Table 5). FGF-2
retention in the hollow fibers was virtually eliminated under
medium (,1.7 mL/min, 3.4 mm/sec) and higher flow rates
(3.0 mL/min, 6 mm/sec), a significant reduction compared to
binding at 0.62 mL/min (1.24 mm/sec) (Table 3- control group).
The simulations, in contrast, did show some level of binding even
at the highest level but this likely reflects the idealized conditions
used for the model system (i.e. uniform receptor and HPSG
densities, free access to coupling between FGF-2 bound mole-
cules). Heparinase treatment showed no significant further
reduction in retention at the higher flow rates in agreement with
the simulation results.
Simulations indicated no difference in FGF-2 binding under our
pulsatile flow conditions versus steady flow (data not shown).
Additional experiments were performed using a syringe pump with
steady flow rather than pulsatile flow. FGF-2 outflow measure-
ments indicated no overall change at 0.62 mL/min (1.2 mm/sec)
(data not shown). Qualitatively the experimental results agreed
with the simulation predictions for the overall effect of flow rate on
retention although the model suggested higher retention levels for
the control case and closer agreement between control and
heparinase at both higher flow rates.
Changes in FGF-2 affinity for HSPG are predicted to have
a larger impact on retention than similar changes in
affinity for FGFR at physiological cell densities
FGF-2 binding affinity and concentration, along with binding
partner density, regulates the capture process for FGF-2 from the
fluid phase. We therefore examined using our simulations how
varying the affinity of FGF-2 for either HSPG (Figure 10A) or
FGFR (Figure 10B) while holding all other parameters at their
baseline value would impact retention. Decreasing the affinity (i.e.
Table 4. VEGF but not EGF retention is impacted by heparinase (experimental).
Treatment Growth Factor input(ng) % Growth Factor Retained Flow rate (mL/min)
EGF 1.4+/20.15 19+/28.1 0.61+/20.01
+Enzymes 1.6+/20.17 20+/27.2 0.62+/20.01
VEGF 1.2+/20.19 16+/25.8 0.66+/20.00
+Heparinase 1.0+/20.26 22.5+/26.1* 0.65+/20.02
Mean +/2 standard deviation of at least three experimental runs.
*indicates significantly (p,0.05) different than non-enzyme treated case.
doi:10.1371/journal.pcbi.1000971.t004
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reducing it to 40% of baseline capture at the lowest value
examined. The association rate constant had a greater impact than
the dissociation rate constant although both followed similar
trends. Somewhat surprisingly, increasing the affinity of the
interaction by reducing the value of the dissociation rate constant
of FGF-2 for HSPG did not alter FGF-2 binding likely due to the
strong coupling present between FGFR and HSPG in the presence
of FGF-2, making strict HSPG-dissociation somewhat irrelevant.
For the same reason, FGF affinity for FGFR did not have a strong
impact on FGF-2 capture since the vast majority of FGF-2
interacting with FGFR was via FGF-2-HSPG coupling.
Figure 5. Simulations agree well with FGF-2 outflow measurements. (A) FGF-2 (0.92 ng) was injected into the cartridge reservoir and then
flowed through the cell-lined hollow fibers at 0.63 mL/min (1.26 mm/sec), pulsatile flow. FGF-2 collected from the exit fluid (N) is shown. Simulation
results based on cells expressing 1610
4 FGFR/cell and 2.5610
5 HSPG/cell with 32% loss in the entrance reservoir having the same FGF-2 amount
injected at the same flow rate (#) are also shown. (B) Similar outflow FGF-2 measurements are shown following FGF-2 (0.92 ng) addition for
heparinase-treated (experimental -N) and simulation results with out HSPG (simulations - #). Simulations were run with cells expressing 1610
4
FGFR/cell and 30% loss in the entrance reservoir.
doi:10.1371/journal.pcbi.1000971.g005
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2 retention
Cells typically express significantly more HSPG than FGFR and
we next asked how varying the cell surface densities of these
binding sites would impact FGF-2 capture. In the absence of
FGFR, a typical density of HSPG in our cartridge (2.5610
5 #/
cell) resulted in significant binding of FGF-2 in the absence of
FGFR that is essentially doubled when FGFR density is 1610
6 #/
cell, a two-fold increase in binding sites (Figure 11A). FGFR
typically are expressed at densities of approximately 1610
4 #/cell
Figure 6. Simulation and experimental comparison between
pulsatile and steady flow. (A) Simulation results of FGF-2 in the
outflow as a function of time for pulsatile (#) or steady (N) flow, (B)
Simulation results of FGF-2 bound along the endothelial-lined hollow
fiber as a function of distance at 44 sec (pulsatile (#), steady (pink
circle) flow) and at 88 seconds (pulsatile (%), steady (green square)
flow) as a function of time, C Experimental comparison of FGF-2 in
outflow using pulsatile (#) and steady (N) flow. Simulations and
experiments used 1 ng of FGF-2 at a flow rate of 0.6 mL/min (1.2 mm/
sec) and pulsatile flow was set at ,36 strokes/min.
doi:10.1371/journal.pcbi.1000971.g006
Figure 7. Simulations show FGF-2 binding and internalization
under flow. For the simulations, FGF-2 (1 ng) was introduced into the
reservoir (30% nonspecific loss) and sent into the cell-lined hollow fibers
under pulsatile flow (0.63 mL/min, 1.26 mm/sec). (A) The sum of all cell
surface bound FGF-2 (N) and FGF-2 internalized (#) within the cell-
lined hollow fiber are shown. (B, C) Plot of % FGFR bound to FGF-2
versus time at the entrance (N), middle (m) and at the exit (&) cell
when the diffusion coefficient is 1.67610
210 (B) or 1.67610
29 m
2/s (C).
The fluid entering the system is essentially free of FGF-2 by 150s after
flow is initiated.
doi:10.1371/journal.pcbi.1000971.g007
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level. This is predicted to result in an order of magnitude less
overall FGF-2 binding than that found at typical HSPG levels but
which is increased in a similar way when HSPG are present. The
combination of the two surface binding sites (FGFR and HSPG) is
critical. For example, when 1.0610
4 FGFR are present, the
retained FGF-2 is increased to ,0.25ng from a value of ,0.14ng
without the FGFR. Looking at cell binding at the entrance of the
cell-lined hollow fiber as a function of time after FGF-2 has been
introduced with constant FGFR (1610
4 #/cell) and variable
HSPG, we found that there was a significant increase in bound
FGF-2 at the higher HSPG (1610
5 #/cell) when compared to the
lower values and that the FGFR binding was essentially all coupled
to HSPG (Figure 11B). When there are fewer HSPG, there is a
Figure 8. Simulations predict FGF-2 concentration profile in
the cell-lined hollow fiber is impacted by diffusion. Grayscale
images of FGF-2 concentration within the cell-lined hollow fiber (1610
4
FGFR/cell and 2.5610
5 HSPG/cell) at 44s after FGF-2 (1 ng) addition
from the reservoir (30% nonspecific loss) at 0.63 mL/min (1.26 mm/sec)
with FGF-2 having a diffusion coefficient of 1.67610
210 (A) or
1.67610
29 m
2/s (B). The scale and numbers on the plots indicates the
concentration of FGF-2 in ng/mL.
doi:10.1371/journal.pcbi.1000971.g008
Figure 9. Simulations show reduced binding with increased
flow rate. (A) Simulations for control (N), and HSPG-deficient cells (#),
were run modeling injection of FGF-2 (1 ng) into the system and run at
varied flow rate. 30% non-specific loss of FGF-2 in the reservoir was
incorporated. (B) Cell-bound+internalized FGF-2 as a function of
injection concentration at 5 min as a function of flow rate is shown.
Simulations performed at 0.63 (N), 1.8 (#), and 3.0 (&) mL/min
pulsatile flow(1.26, 3.6, and 6 mm/sec, respectively). Each cell on the
cell-lined hollow fiber expressed 1610
4 FGFR/cell and 2.5610
5
HSPG/cell.
doi:10.1371/journal.pcbi.1000971.g009
Table 5. Increased flow rate eliminates FGF-2 binding
(experimental).
Treatment
FGF-2
input(ng)
% FGF-2
Retained
Flow rate
(mL/min)
Control 1.1+/20.11 6.7+/24.6 1.7+/20.10
+Heparinase 1.1+/20.02 6.7+/21.2 1.8+/20.05
Control 0.91+/20.17 0.5+/29.1 2.9+/20.13
+Heparinase 0.95+/20.25 0.5+/210 3.0+/20.03
Mean +/2 standard deviation of at least two experimental runs.
doi:10.1371/journal.pcbi.1000971.t005
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as lower overall FGFR complexes.
Simulations predict coupling is key to effective capture
of FGF-2
The results with the FGF-2-HSPG affinity simulations and the
density studies indicated the importance of coupling in facilitating
effective FGF-2-FGFR interactions. We next looked at how
varying the coupling rate constant impacted binding and
internalization using simulations (Figure 12). In the absence of
HSPG-FGFR coupling (kc=0), there is a reduction in peak
binding of FGF-2 and the majority of FGF-2 bound is not
internalized but dissociates and exits from the system in the
outflow. Even with a low level of coupling, the FGF-2 binding and
Figure 10. Simulations predict binding affinity of FGF-2 for HSPG impacts FGF-2 capture more than affinity for FGFR. (A) The affinity
of FGF-2 for HSPG was varied in simulations by changing the association rate constant (N) or the dissociation rate constant (#). (B) The affinity of
FGF-2 for FGFR was varied by changing the association rate constant (N) or the dissociation rate constant (#). The FGF-2 captured within the cell-
lined hollow fiber (bound or internalized) at the given KD value after 5 min. was scaled by that same value from simulations using the base case KD
value (Table 2). Arrow indicates base case KD.
doi:10.1371/journal.pcbi.1000971.g010
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with kc=0.01(#/cell)
21 min
21. If we looked at later times in the
simulation (Figure 12B), we would find that a large fraction of the
FGF-2 injected is bound during the initial pass and that this bound
FGF-2 is largely internalized with little exiting the system. If
coupling between HSPG and FGFR is eliminated (Figure 12C),
this is not the case. In this scenario, the cells bind a smaller but still
significant level of FGF-2 during the initial pass but this FGF-2 is
not retained and nearly all of the FGF-2 captured ultimately exits
the system in the outflow.
To further illustrate the importance of the coupling process,
simulations were performed with cell-lined hollow fibers having
only HSPG (2.5610
5 #/cell) in the front 25% of the tube and
both FGFR (1610
4 #/cell) and HSPG (2.5610
5 #/cell) in the
back 75% of the fiber (Figure 13). The entrance area (front 25%)
did not include internalization of FGF-2 by HSPG modeling an
ECM-like section, however, the overall outcomes are not
significantly changed when internalization is included (data not
shown). HSPGs in this front section were able to capture FGF-2
but there is a significant rise in retention in the back section where
both HSPG and FGFR are present. This is not simply due to the
increase in binding sites due to the addition of FGFR as increasing
HSPG by an equivalent level to that of the HSPG plus FGFR did
not lead to the same increase in retention (data not shown).
Moreover, this increase in retention is lost when the dissociation
rate for FGF-2-FGFR-HSPG is reduced to that of FGF-2-HSPG
and only nominally increased when the coupling rate is eliminated,
reflecting the increased affinity of FGFR compared to HSPG for
Figure 11. Simulations predict cell surface density impacts FGF-2 retention. Simulations were run for FGF-2 (1ng) added to the system
(30% non-specific loss) at 0.63 mL/min pulsatile flow (1.26 mm/sec) for 5 min. (A) Cells expressed either 1610
4 FGFR/cell and variable densities of
HSPG (#) or 2.5610
5 HSPG/cell and variable densities of FGFR (N) on the cell-lined hollow fibers. The amount retained within the system (bound,
internalized, and fluid phase FGF-2) is shown. (B) Cells expressed 1610
4 FGFR/cell and 2610
3 (N,#), 2610
4 (&,%), or 2610
5 (m,n) HSPG/cell on the
cell-lined hollow fibers and simulation results correspond to entrance cell value at a given time. Filled symbols correspond to % of FGF-2 bound to
FGFR which are simultaneously bound to HSPG and open symbols correspond to the #/cell of FGF-2 bound to FGFR and HSPG.
doi:10.1371/journal.pcbi.1000971.g011
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flow rates.
Finally, we used simulations to ask whether dissociation from
HSPG in an ECM-like section could lead to increased binding
downstream due to slow dissociation of the growth factor and
prolonged availability of the growth factor for downstream
binding. When the HSPG density in the front 25% zone was
increased to 5610
6 HSPG/cell, a large increase in overall
retention of FGF-2 in the front section was evident resulting in a
decrease in FGF binding in the HSPG-FGFR section (back 75%)
due to a depletion of FGF-2 in the fluid zone near the cells. This
was evident at both 5 (Table 6) and 10 min (data not shown). In
contrast, a low level of HSPG (5610
4 or less) in the entrance
section did not lead to significant binding in this zone and results
in increased binding of FGF-2 in the final 75% section. FGF-2 in
the fluid phase was at a higher concentration at later times after
FGF-2 injection when there were more HSPG in the front section
due to dissociation from the HSPGs; however, under flow
conditions, this dissociated FGF-2 is not predicted to grow to a
high enough concentration to meaningfully impact downstream
receptor binding. This is an important difference between flow
and static culture studies.
Discussion
Circulation is an obligatory process for the maintenance of
human life. The proper balance of solid and fluid components,
flow and pressure, and chemical content are all tightly regulated to
maintain homeostasis. Within these limits, however, wide
fluctuations can occur. The effects of the regulatory processes
that are in place to deal with these fluctuations are not well
characterized. Often the overall effects can be easily measured but
not the changes in the microenvironment that come together to
drive these effects. Although traditional tissue culture studies have
added a wealth of knowledge in such areas, they often lack the
capability to emulate the in vivo environment. In the study of the
effect of flow in regulating vessel wall interactions, for example,
three-dimensional studies can provide valuable information.
Three-dimensional studies have been used previously to measure
the effects of flow on cell populations [18,36–39]. We have chosen
such an approach to measure the effect of flow on heparin binding
protein delivery. By employing a single pass method to focus on
the initial growth factor-vessel wall interaction we were able to
more directly measure the effect of flow on the bioavailability of
these growth factors. We measured substantial binding of all
growth factors (FGF-2, VEGF, and EGF) at the lowest flow rate
tested (0.61–0.66 mL/min, 1.22– 1.32 mm/sec). Had a traditional
two-dimensional approach been used instead, these factors would
have had few limitations on their rebinding potential since in a
closed system they would not be subject to the flow that would
remove them from the vessel as is typical of normal circulation. In
the case of the heparin binding proteins (FGF-2 and VEGF),
removal of heparan sulfate sites via enzyme digestion resulted in a
significant increase in growth factor outflow (i.e. non-retention
within the vessel), suggesting an important regulatory role for these
proteoglycans in ligand capture. This is not necessarily surprising
given the large number of binding sites these proteoglycans
provide on normal cell surfaces. Certainly, it has been shown by us
and others that HSPGs are important regulators of FGF-2 binding
to FGF receptors in tissue culture [28], although not essential for
the interaction [6,24,27]. Their importance with regard to capture
under flow has, however, not been shown previously and suggests
a critical role in the circulation.
Figure 12. Simulations indicate coupling is critical for FGF-2
retention. (A) FGF-2 bound on cell surfaces plus internalized FGF-2 as a
function of time for kc values of 0 (#), 0.0001(N), 0.001(%), and 0.1(&)
(#/cell)
21 min
21; (B,C) FGF-2 bound (&), internalized (N), bound plus
internalized (#) and exited (%) under flow with kc=0.0024 (B) or 0 (C)
(#/cell)
21min
21 following addition of FGF-2 (1ng) at 0.63 mL/min
(1.26 mm/sec) pulsatile flow(30% non-specific loss). Capillaries were
simulated to include 1610
4 FGFR/cell and 2.5610
5 HSPG/cell on the
cell-lined hollow fibers. 300s corresponds to the time when essentially
all of the FGF-2 has entered the hollow fiber from the reservoir.
doi:10.1371/journal.pcbi.1000971.g012
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binding, regardless of heparin binding characteristics however,
was the flow rate. By increasing the flow rate by less than a factor
of three (,1.8 mL/min, 3.6 mm/sec) a significant increase was
seen in growth factor outflow, reflecting the absence of specific
binding taking place on vessel surfaces. A higher flow rate
(,3.0 mL/min, 6 mm/sec) showed no further increase in FGF-2
outflow above that observed at the medium flow rate with both
showing retention levels equivalent to that evident in the absence
of heparan sulfate. This correlation of flow rate and outflow of
growth factors suggests a strong regulatory effect and an
environment in the bloodstream that reduces the probability of
capture significantly at flow rates typically measured in arteries [4].
Although pulsatile flow is undoubtedly important in increasingly
larger vessels and higher flow rates, both simulations and
experiments showed that at the low flow rate typical of capillaries
it had no significant effect on FGF-2 interactions when compared
to steady flow.
The removal of chondroitin sulfate created a small but
significant increase in FGF-2 outflow. This is interesting since a
number of published findings found no significant affinity between
FGF-2 and chondroitin sulfate [30,31]. It is possible that under
flow conditions subtle changes in chondroitin sulfate modifications
allow for some weak interaction. Others have reported the ability
of FGF-2 to bind chondroitin sulfate under certain circumstances
[32–34]. EGF binding was, however, unaffected by treatment with
a heparinase, chondroitinase and keratanase cocktail suggesting
the chondroitinase effect was not universal. How this effect is
manifest is currently under further study.
The minimum size of capillaries has been shown to be relatively
fixed across species regardless of size [40] and is a basic
assumption in the general model of allometric scaling laws
proposed by West et al [41]. This suggests an optimum
environment for the exchange of gases, nutrients, and the removal
of waste products that is likely rooted in fundamental physical
laws. In order to best make use of these environmental conditions
blood flow must also be optimal. Our data demonstrate an inverse
correlation between flow rate and probability of capture. Although
the presence of heparan sulfate is crucial to FGF-2 capture at low
flow rates, at higher flow rates the overriding regulator seems to be
the flow rate itself which, based on our results, would all but
preclude efficient FGF-2 binding to vessel walls in a single pass
under all but the slowest flow conditions. The expectation of lower
binding at increasingly higher flow rates might be somewhat
expected but the relatively small increase in flow rate required to
ablate binding was surprising.
Other influences, such as viscosity, and the presence of
competing molecules were not addressed in this work. These are
ongoing studies as we begin to add complexity to the system so as
to form even more accurate models of circulation. The advantage
of this method is that the conditions can be monitored and
controlled much as two dimensional culture systems can be but
include the three dimensional architecture and flow characteristics
that are part of normal blood flow. This approach has obvious
potential in the testing of both endogenous molecules and
pharmaceuticals in order to provide a better perspective of
molecular interactions in the microenvironment of blood vessels.
The importance of HSPGs in FGF-2 binding and signaling has
been shown in many systems [6–11] and is a generally accepted
feature for heparin-binding growth factors. Our work builds upon
those studies and shows the critical importance of HSPGs in FGF-
2 capture under flow (Figure 3). In this paper, we explore the
impact of this critical component in detail using our computational
model and show the parameters that regulate this process. In
particular we show that the two-step coupling process and the
accompanying decrease in dissociation are essential for effective
retention of FGF-2 in a flow situation.
HSPG can mediate both the heparin-binding growth factor-
receptor interaction at the cell surface and the accumulation and
storage of these growth factors in the extracellular matrix [42,43].
Removal of HSPG from the cell surface by enzymatic digestion
greatly impairs FGF-2 activity in vitro and inhibits neo-vascular-
ization in vivo [27,28,44]. HSPG interacts with FGFR directly
[45,46] and FGF-2 binding to cell surface HSPG can facilitate
FGF-2 binding to FGFR, which in turn can result in activation of
intracellular signaling cascades. Using our simple model under
flow, we show in several ways that the coupling step is critical for
FGF-2 retention. Elimination of coupling or decreasing the rate
constant describing that interaction has a dramatic effect on both
FGF-2 bound and internalized with essentially no internalization
or effective binding when coupling is eliminated (Figure 12).
Reducing the density of HSPG (Figure 11) or the affinity of FGF-2
for HSPG (Figure 9) significantly reduces the amount of FGF-2
bound to both the cell surface and to FGFR. In addition,
simulations with only low levels of HSPG (Figures 11, 12 –
entrance zone) or FGFR (data not shown) do not exhibit high
Figure 13. Simulations predict both FGFR and HSPG contribute
to retention through FGF-2-mediated coupling. In these simula-
tions, HSPG (2.5610
5 #/cell) were expressed on the cell-lined fibers
along the entire chamber while FGFR (1610
4 #/cell) were expressed
only in the cells found in the final 75% of the hollow fiber. FGF-2 (1ng)
was added at time 0 (30% loss in the reservoir) at 0.65 (N), 1.3 (#), and
2.6 (&) mL/min pulsatile flow (1.3, 2.6, and 5.2 mm/sec respectively).
Cell-bound+internalized FGF-2 after 5 min of simulation time is shown.
doi:10.1371/journal.pcbi.1000971.g013
Table 6. Simulations predict effect of entrance HSPG zone on
FGF-2 capture at 5 min.
HSPG Density in Front 25% of
Cell-lined Hollow Fiber
5610
6 5610
5 5610
4
Total FGF-2 Retained (ng) 0.39 0.34 0.31
FGF-2 Bound (ng) (Front 25%) 0.16 0.063 0.0022
FGF-2 Bound (ng) (Back 75%) 0.17 0.24 0.28
FGF-2 Internalized (ng) (Back 75%) 0.013 0.017 0.022
FGF-2 in Fluid Phase (ng) 0.029 0.022 0.008
doi:10.1371/journal.pcbi.1000971.t006
Flow and Heparan Sulfate Regulate Vascular Binding
PLoS Computational Biology | www.ploscompbiol.org 16 October 2010 | Volume 6 | Issue 10 | e1000971retention but, when both HSPG and FGFR are present (Figure 13),
the combination of both increases retention. This is evident
independent of flow rate. The ability of flow to regulate the level of
binding suggests how crucial the presence of HSPG is on the vessel
wall, in order to increase the probability of capture of heparin-
binding molecules especially given the short half-lives of some
growth factors in circulation.
Under the flow condition, simulations predict that the majority
of FGF-2 binding occurs at the entrance to the cell-lined hollow
fiber (Figure 7). In our simulations set up to match the
experimental conditions, FGF-2 enters at its highest concentration
and thus is most likely to bind under those conditions. Once
binding occurs, there is a depletion of FGF-2 in the fluid phase
near the cell surface (Figure 8). Under flow, this zone can be
replenished via diffusion as increasing the diffusion coefficient
increases the concentration in this zone (Figure 8) and ultimately
leads to higher binding down the cell-lined hollow fiber. We had
postulated that FGF-2 bound in the entrance zone of the cell-lined
hollow fiber would eventually dissociate and rebind further down
the tube but this does not appear to be the case. Even when
binding is extremely high at the entrance, FGF-2 that dissociated
from the entrance was not in high enough concentration to impact
downstream binding and was eventually washed out of the system
(data not shown). In a non-flow system this would likely not be the
case and exemplifies the importance of including flow in studies.
In conclusion, a simulation program previously developed by us
but enhanced for our specific cell investigations of FGF-2 binding
under flow [16,17] performed well when compared to our
experimental endothelial cell-lined bioreactor. Our simulations
suggest that: (1) The amount of FGF-2 bound to FGFR is
dominated by HSPG and the coupling rate constant, and this triad
(FGFR-HSPG-FGF-2) is the key to FGF-2 capture; (2) The
amount of FGF-2 bound is proportional to the diffusivity of the
growth factor in solution and inversely proportional to the flow
rate; (3) Flow rate and diffusivity will affect the FGF-2 outflow
profile and the distribution of FGF-2 bound along the cell-lined
hollow fiber wall; (4) The majority of FGF-2 binding occurs in the
entrance zone of the cell-lined hollow fiber; and (5) most FGF-2
effectively bound by FGFR and HSPG will be internalized rather
than dissociated. The simulation environment can provide
additional information and insight into capture of FGF-2 that is
not easily accessible from experimental work. We have applied the
model to our in vitro bioreactor system but it has potential to be
used for other growth factors as well as other cell systems where
flow and capture are pivotal such as in drug and biologicals
delivery testing.
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